<code id='6541C421A0'></code><style id='6541C421A0'></style>
    • <acronym id='6541C421A0'></acronym>
      <center id='6541C421A0'><center id='6541C421A0'><tfoot id='6541C421A0'></tfoot></center><abbr id='6541C421A0'><dir id='6541C421A0'><tfoot id='6541C421A0'></tfoot><noframes id='6541C421A0'>

    • <optgroup id='6541C421A0'><strike id='6541C421A0'><sup id='6541C421A0'></sup></strike><code id='6541C421A0'></code></optgroup>
        1. <b id='6541C421A0'><label id='6541C421A0'><select id='6541C421A0'><dt id='6541C421A0'><span id='6541C421A0'></span></dt></select></label></b><u id='6541C421A0'></u>
          <i id='6541C421A0'><strike id='6541C421A0'><tt id='6541C421A0'><pre id='6541C421A0'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:comprehensive    - browse:2
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

          The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

          advertisement

          Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time